{
  "docId": "019de071-1bdd-70bb-9c61-980d0c38b663",
  "docSlug": "a4792f18c57ea3f4ba27e696a63520de",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4148858,
  "pageNumber": 37,
  "pageCount": 40,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "other",
  "function": "other",
  "density": "dense",
  "nDataPoints": 22,
  "notes": "The slide uses a color-coded legend to map drug candidates to specific oncology research areas.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1bdd-70bb-9c61-980d0c38b663/37",
  "deckHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663",
  "deckJsonHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663.json",
  "deckAnchorHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.85,
        "w": 0.425,
        "x": 0.545,
        "y": 0.125
      },
      "kind": "image",
      "text": "Composite image of a patient and medical professionals",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d47b1261-0641-4868-b41f-4485debb5c10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.058,
        "y": 0.68
      },
      "kind": "legend",
      "text": "Immuno-oncology, Oncolytic virus, Epigenetics, Haematology, Tumour drivers and resistance, DNA damage response",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2119991b-fb87-4cf0-b964-93837d0a98ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.038,
        "y": 0.825
      },
      "kind": "source-note",
      "text": "1. Adenosine A2A receptor 2. Cytotoxic T-lymphocyte-associated protein 4.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33dd6d34-0c99-4107-b56e-a8f5f03d3498",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.062,
        "y": 0.295
      },
      "kind": "table",
      "text": "Pipeline table showing Phase I and Phase II drug candidates",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81efa9af-d12e-4a28-9037-76033ea642da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.468,
        "x": 0.048,
        "y": 0.145
      },
      "kind": "title",
      "text": "Early-stage oncology pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "193a89ad-ca0b-4ab1-b3c7-c45f59af7f1c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "8a7accb5-1163-48aa-9483-af99f9b9d958",
      "evidence": "table/data: Pipeline table showing Phase I and Phase II drug candidates",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "9bb24be0-c8c7-49aa-a526-e9fcc4794b51",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document concludes with a call to action and next steps for investors.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}